ARC Group Acquisition I flagged on $1m Nasdaq warrant rule
ARC Group Acquisition I Corp. (ARCL) reported that on August 27, 2026 it received a Nasdaq deficiency notice because the aggregate market value of its outstanding warrants fell below the $1 million minimum required under Nasdaq Listing Rule 5452(b)(C).
Rhea-AI Filing Summary
ARC Group Acquisition I Corp. (ARCL) reported that on August 27, 2026 it received a Nasdaq deficiency notice because the aggregate market value of its outstanding warrants fell below the $1 million minimum required under Nasdaq Listing Rule 5452(b)(C). The company has 45 days, until October 12, 2026, to submit a compliance plan, after which Nasdaq may grant up to 180 additional days, through February 23, 2027, to regain compliance. The notice affects only the company’s warrants (ARCLW) and does not currently impact the listing or trading of its other securities. The company intends to submit a plan but notes there is no assurance it will regain or maintain compliance; a delisting determination could be appealed to a Nasdaq hearings panel.
Positive
- None.
Negative
- Nasdaq notified the company that its warrants no longer meet the $1 million aggregate market value requirement under Listing Rule 5452(b)(C), creating a risk of future warrant delisting if compliance is not regained.
Insights
Analyzing...
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum aggregate market value of outstanding warrants required: $1,000,000
Plan submission deadline: October 12, 2026
Maximum potential compliance extension period: 180 days to February 23, 2027
+1 more
4 metrics
Minimum aggregate market value of outstanding warrants required
$1,000,000
Nasdaq Global Market continued listing standard under Listing Rule 5452(b)(C)
Plan submission deadline
October 12, 2026
45 calendar days from August 27, 2026 deficiency notice to submit plan to Nasdaq
Maximum potential compliance extension period
180 days to February 23, 2027
Latest date Nasdaq may allow to evidence compliance if it accepts the plan
Warrant exercise price
$11.50 per share
Each warrant exercisable for one Class A ordinary share at this price
Key Terms
Nasdaq Listing Rule 5452(b)(C), aggregate market value of its outstanding warrants, continued listing criteria, hearings panel, +1 more
5 terms
Nasdaq Listing Rule 5452(b)(C) regulatory
"continued listing criteria set forth in the Nasdaq Listing Rule 5452(b)(C)"
aggregate market value of its outstanding warrants financial
"since the Company’s aggregate market value of its outstanding warrants was less than $1 million"
continued listing criteria regulatory
"no longer in compliance with the Nasdaq Global Market continued listing criteria"
A set of financial, reporting and corporate-governance requirements that a company must meet to remain listed on a stock exchange. Think of it like the rules and upkeep for a membership card: if a company fails to maintain minimum share price, market value, timely reports or other standards, the exchange can warn, suspend or remove the stock. For investors this matters because falling below these standards can reduce liquidity, increase risk and lead to sudden price drops or forced sales.
hearings panel regulatory
"Nasdaq rules permit the Company to appeal the decision to a hearings panel"
A hearings panel is a review body at a stock exchange that hears the case when the exchange has decided a company no longer qualifies to keep its shares listed. The company presents a plan to regain compliance, and the panel decides whether the listing continues, on what conditions, and for how long. The decision can keep a stock trading or end its listing.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What Nasdaq deficiency did ARC Group Acquisition I Corp. (ARCL) disclose?
Nasdaq notified the company on August 27, 2026 that the aggregate market value of its outstanding warrants had fallen below the required $1 million threshold under Nasdaq Listing Rule 5452(b)(C), triggering a continued listing deficiency for its warrants.
Which ARC Group Acquisition I Corp. (ARCL) securities are affected by the Nasdaq notice?
The notice applies only to the company’s warrants (ARCLW). ARC Group Acquisition I Corp. states that the deficiency notice has no current effect on the listing or trading of its other securities, including its units, Class A ordinary shares, and rights.
How long does ARC Group Acquisition I Corp. (ARCL) have to address the Nasdaq warrant deficiency?
The company has 45 calendar days from the August 27, 2026 notice, or until October 12, 2026, to submit a plan to regain compliance. If Nasdaq accepts the plan, it may grant up to 180 days, through February 23, 2027, to evidence compliance.
Is ARC Group Acquisition I Corp. (ARCL) facing immediate delisting of its warrants?
No. The company states the notice is a notification of deficiency only and has no current effect on the listing or trading of its warrants. However, if it fails to regain compliance, Nasdaq could later notify the company that the warrants are subject to delisting.
Can ARC Group Acquisition I Corp. (ARCL) appeal if Nasdaq decides to delist its warrants?
Yes. The company explains that if Nasdaq rejects its compliance plan or later determines to delist the warrants, Nasdaq rules allow an appeal to a hearings panel to challenge any delisting determination.
AI-generated analysis. How Rhea-AI works. Not financial advice.
